(NASDAQ: OKUR) Onkure Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.28%.
Onkure Therapeutics's earnings in 2026 is -$58,749,000.On average, 6 Wall Street analysts forecast OKUR's earnings for 2026 to be -$103,145,819, with the lowest OKUR earnings forecast at -$126,284,350, and the highest OKUR earnings forecast at -$81,437,288. On average, 5 Wall Street analysts forecast OKUR's earnings for 2027 to be -$87,763,220, with the lowest OKUR earnings forecast at -$96,989,547, and the highest OKUR earnings forecast at -$78,892,372.
In 2028, OKUR is forecast to generate -$89,686,045 in earnings, with the lowest earnings forecast at -$91,843,163 and the highest earnings forecast at -$87,799,576.